Item 2.01. Completion of Acquisition or Disposition of Assets.
On March 12, 2021, Veracyte, Inc., a Delaware corporation ("Veracyte") completed
its previously announced acquisition of Decipher Biosciences, Inc., a Delaware
corporation ("Decipher"), pursuant to the terms of an Agreement and Plan of
Merger (the "Merger Agreement") dated as of February 2, 2021.
Pursuant to the terms of the Merger Agreement, Decipher became a wholly owned
subsidiary of Veracyte. At the closing, all outstanding shares of Decipher
capital stock and options to purchase Decipher capital stock were cancelled in
exchange for approximately $600 million in cash to existing Decipher
securityholders, subject to customary purchase price adjustments. Fortis
Advisors LLC, is acting as the stockholders' agent.
The foregoing summary of the Merger Agreement and the transactions contemplated
thereby do not purport to be complete and are subject to, and qualified in their
entirety by, the full text of the Merger Agreement, which will be filed as an
exhibit to Veracyte's Quarterly Report on Form 10-Q for the three months ended
March 31, 2021.
© Edgar Online, source Glimpses